Similarly, two other biomarker panels in the 2-biomarker combination cohort of methylated SDC2 and TFPI2 exhibited CRC detection rates of 90% and over, with 70.6% APL detection for Yang et al. [73] and 81.3% all adenomas detection (no APL-specific data) for Zhang et al. [77], emphasising the strong diagnostic capability of this biomarker combination. This evidence concerns the gene TFPI2 and adenoma.